<DOC>
	<DOCNO>NCT00235443</DOCNO>
	<brief_summary>Phase 2/3 open-label trial ass safety tolerability long-term treatment lacosamide ( SPM 927 ) subject painful diabetic neuropathy . The safety tolerability different dos lacosamide investigate .</brief_summary>
	<brief_title>A Follow-On Trial Assess Long Term Safety Efficacy SPM 927 Painful Distal Diabetic Neuropathy</brief_title>
	<detailed_description>This phase 2/3 open-label trial conduct approximately 100 site US ass safety tolerability long-term treatment lacosamide ( SPM 927 ) subject painful diabetic neuropathy . Approximately 525 subject enrol . To qualify trial , subject symptom painful distal diabetic neuropathy range duration 6 month 5 year must complete trial SP665 , SP742 , SP768 , investigator 's opinion , may benefit long-term administration lacosamide . Subjects titrate optimal dose lacosamide ( 600mg/day ) . The safety tolerability different dos lacosamide investigate throughout trial . In addition , determine effect lacosamide diabetic neuropathic pain , subject use diary record daily pain intensity pain interference sleep activity . Subjects ' quality life also investigate .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subjects complete Study SP665 , SP742 , SP768 , investigator opinion , might benefit longterm administration SPM 927 . Exception : subject prematurely discontinue Study SP742 SP768 due lack efficacy due intolerability trial medication may eligible participate Study SP745 , consultation medical monitor . Subject clinically relevant electrocardiogram ( ECG ) abnormality , QTcorrected ( QTc ) interval &gt; =500 millisecond ( m ) , and/or QTc interval increase &gt; =60ms mean predose QTc value Visit 2 Studies SP665 , SP742 SP768 . Subject aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; =3 time upper limit normal range ( ULN ) total bilirubin &gt; =2 time ULN transaminase ( AST and/or ALT ) &gt; =5 time ULN . Subject clinically relevant medical condition , opinion investigator , jeopardize compromise subject 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Painful Distal Diabetic Neuropathy</keyword>
</DOC>